MX2022002342A - Composiciones y metodos para suministro de acidos nucleicos a celulas. - Google Patents
Composiciones y metodos para suministro de acidos nucleicos a celulas.Info
- Publication number
- MX2022002342A MX2022002342A MX2022002342A MX2022002342A MX2022002342A MX 2022002342 A MX2022002342 A MX 2022002342A MX 2022002342 A MX2022002342 A MX 2022002342A MX 2022002342 A MX2022002342 A MX 2022002342A MX 2022002342 A MX2022002342 A MX 2022002342A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- compositions
- cells
- methods
- delivery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona composiciones y métodos de uso de las mismas para suministrar carga de ácido nucleico en las células. Las composiciones típicamente incluyen (a) un anticuerpo monoclonal 3E10 o un fragmento de penetración en célula, de enlace de antígeno del mismo; un fragmento variable de una sola cadena (scFv) monovalente, divalente o multivalente; o un diacuerpo; o forma humanizada o variante del mismo y (b) una carga de ácido nucleico que incluye, por ejemplo, un ácido nucleico que codifica un polipéptido, un ácido nucleico funcional, un ácido nucleico que codifica un ácido nucleico funcional, o una combinación de los mismos. Los elementos (a) y (b) típicamente se enlazan no covalentemente para formar un complejo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/048962 WO2020047353A1 (en) | 2018-08-31 | 2019-08-30 | Compositions and methods for enhancing triplex and nuclease-based gene editing |
PCT/US2019/048953 WO2020047344A1 (en) | 2018-08-31 | 2019-08-30 | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
US201962944281P | 2019-12-05 | 2019-12-05 | |
PCT/US2020/048823 WO2021042060A1 (en) | 2019-08-30 | 2020-08-31 | Compositions and methods for delivery of nucleic acids to cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002342A true MX2022002342A (es) | 2022-06-14 |
Family
ID=74684750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002342A MX2022002342A (es) | 2019-08-30 | 2020-08-31 | Composiciones y metodos para suministro de acidos nucleicos a celulas. |
Country Status (10)
Country | Link |
---|---|
US (5) | US20230227583A1 (es) |
EP (1) | EP4021496A1 (es) |
JP (1) | JP2022546699A (es) |
KR (1) | KR20220101073A (es) |
CN (1) | CN115151275A (es) |
AU (1) | AU2020336992A1 (es) |
CA (1) | CA3149421A1 (es) |
IL (1) | IL290862A (es) |
MX (1) | MX2022002342A (es) |
WO (1) | WO2021042060A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115151275A (zh) | 2019-08-30 | 2022-10-04 | 耶鲁大学 | 用于向细胞递送核酸的组合物和方法 |
EP4204002A1 (en) * | 2020-08-31 | 2023-07-05 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
CN117295753A (zh) * | 2020-12-04 | 2023-12-26 | 基那奥生物公司 | 用于将核酸递送到细胞的组合物和方法 |
JP2024508309A (ja) * | 2021-03-03 | 2024-02-26 | イエール ユニバーシティ | 骨格筋疾患を治療するための組成物及び方法 |
EP4346907A1 (en) * | 2021-05-25 | 2024-04-10 | Transmab Pty Ltd | Improved immunoglobulin i |
KR20240043747A (ko) * | 2021-07-02 | 2024-04-03 | 예일 유니버시티 | 암을 치료하기 위한 조성물 및 방법 |
CA3226284A1 (en) * | 2021-07-08 | 2023-01-12 | Temple University - Of The Commonwealth System Of Higher Education | Oligonucleotides and viral untranslated region (utr) for increasing expression of target genes and proteins |
AU2022340804A1 (en) * | 2021-08-31 | 2024-03-21 | Gennao Bio, Inc. | Compositions and methods for treating cancers |
WO2023168401A1 (en) * | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for treating disease |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
ATE171185T1 (de) | 1985-03-15 | 1998-10-15 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4812397A (en) | 1987-02-10 | 1989-03-14 | The Regents Of The University Of California | MAB-anti-DNA related to nephritis |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
DE4331012A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik |
US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
WO1997032602A1 (en) | 1996-03-08 | 1997-09-12 | The Regents Of The University Of California | DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
US5786571A (en) | 1997-05-09 | 1998-07-28 | Lexmark International, Inc. | Wrapped temperature sensing assembly |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
AU5886000A (en) | 1999-06-25 | 2001-01-31 | Northwestern University | Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells |
US6919208B2 (en) | 2000-05-22 | 2005-07-19 | The Children's Hospital Of Philadelphia | Methods and compositions for enhancing the delivery of a nucleic acid to a cell |
EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
US7067617B2 (en) | 2001-02-21 | 2006-06-27 | The Scripps Research Institute | Zinc finger binding domains for nucleotide sequence ANN |
US20040197892A1 (en) | 2001-04-04 | 2004-10-07 | Michael Moore | Composition binding polypeptides |
WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
JP2009520463A (ja) | 2005-11-28 | 2009-05-28 | ザ スクリプス リサーチ インスティテュート | Tnnのための亜鉛フィンガー結合ドメイン |
US20070154989A1 (en) | 2006-01-03 | 2007-07-05 | The Scripps Research Institute | Zinc finger domains specifically binding agc |
CN1986792A (zh) * | 2006-12-14 | 2007-06-27 | 方炳良 | 致病细胞的外来抗原标记方法 |
WO2008091911A2 (en) | 2007-01-22 | 2008-07-31 | The Regents Of The University Of California | Use of antibody conjugates |
EP2443155B1 (en) * | 2009-06-15 | 2017-03-29 | Valerion Therapeutics, LLC | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1 (mtm1) polypeptides |
PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
WO2012135831A1 (en) * | 2011-04-01 | 2012-10-04 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair |
AU2012240135B2 (en) | 2011-04-08 | 2016-09-08 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
US9272043B2 (en) | 2011-12-02 | 2016-03-01 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
US9732146B2 (en) | 2012-03-30 | 2017-08-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Antibody-mediated transduction of heat shock proteins into living cells |
US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
ES2960803T3 (es) | 2012-05-25 | 2024-03-06 | Univ California | Métodos y composiciones para la modificación de ADN diana dirigida por RNA y para la modulación de la transcripción dirigida por RNA |
CA2876734A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Use of cart19 to deplete normal b cells to induce tolerance |
CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
CN105189542A (zh) | 2013-02-20 | 2015-12-23 | 瓦莱里昂治疗有限责任公司 | 用于治疗庞贝氏症的方法和组合物 |
US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
JP6709733B2 (ja) | 2014-01-13 | 2020-06-17 | バレリオン セラピューティクス, エルエルシー | 内在化部分 |
US10040867B2 (en) | 2014-03-04 | 2018-08-07 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations |
SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
CA2989294A1 (en) * | 2014-06-13 | 2015-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
WO2016033324A1 (en) | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
WO2016033321A1 (en) | 2014-08-28 | 2016-03-03 | Yale University | Multivalent fragments of antibody 3e10 and methods of use thereof |
WO2016081621A1 (en) | 2014-11-18 | 2016-05-26 | Yale University | Formulations for targeted release of agents under low ph conditions and methods of use thereof |
WO2017015101A1 (en) | 2015-07-17 | 2017-01-26 | University Of Washington | Methods for maximizing the efficiency of targeted gene correction |
WO2017015630A2 (en) | 2015-07-23 | 2017-01-26 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
JP2019508037A (ja) | 2016-02-16 | 2019-03-28 | イェール ユニバーシティーYale Universit | 標的化遺伝子編集を増強するための組成物およびその使用方法 |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
CA3027960C (en) | 2016-06-15 | 2022-06-14 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
WO2018187493A1 (en) | 2017-04-04 | 2018-10-11 | Yale University | Compositions and methods for in utero delivery |
US20200216568A1 (en) | 2017-07-17 | 2020-07-09 | Nucleus Therapeutics Pty. Ltd. | Binding proteins 2 |
WO2019079215A1 (en) * | 2017-10-16 | 2019-04-25 | Aadigen, Llc | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR MRRNA DELIVERY |
US20210054102A1 (en) | 2018-02-01 | 2021-02-25 | Yale University | Compositions and methods for enhancing nuclear translocation |
US20210137960A1 (en) | 2018-02-01 | 2021-05-13 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
KR20210054547A (ko) | 2018-08-31 | 2021-05-13 | 예일 유니버시티 | 삼중체 및 뉴클레아제 기반 유전자 편집을 향상시키기 위한 조성물 및 방법 |
FI20186112A1 (en) | 2018-12-19 | 2020-06-20 | Actim Oy | SYSTEM AND METHOD FOR ANALYZING THE RESULT OF THE CARE SITE TEST |
CN115151275A (zh) | 2019-08-30 | 2022-10-04 | 耶鲁大学 | 用于向细胞递送核酸的组合物和方法 |
CN111218458B (zh) | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法 |
-
2020
- 2020-08-31 CN CN202080076637.2A patent/CN115151275A/zh active Pending
- 2020-08-31 US US17/638,642 patent/US20230227583A1/en active Pending
- 2020-08-31 CA CA3149421A patent/CA3149421A1/en active Pending
- 2020-08-31 EP EP20771954.3A patent/EP4021496A1/en active Pending
- 2020-08-31 KR KR1020227010637A patent/KR20220101073A/ko active Search and Examination
- 2020-08-31 WO PCT/US2020/048823 patent/WO2021042060A1/en active Application Filing
- 2020-08-31 JP JP2022513157A patent/JP2022546699A/ja active Pending
- 2020-08-31 AU AU2020336992A patent/AU2020336992A1/en active Pending
- 2020-08-31 MX MX2022002342A patent/MX2022002342A/es unknown
-
2022
- 2022-02-24 IL IL290862A patent/IL290862A/en unknown
- 2022-08-30 US US17/823,496 patent/US20230093460A1/en active Pending
- 2022-08-30 US US17/823,488 patent/US11872286B2/en active Active
- 2022-08-30 US US17/823,494 patent/US11850284B2/en active Active
- 2022-08-30 US US17/823,492 patent/US20230032060A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230227583A1 (en) | 2023-07-20 |
JP2022546699A (ja) | 2022-11-07 |
US11872286B2 (en) | 2024-01-16 |
KR20220101073A (ko) | 2022-07-19 |
CN115151275A (zh) | 2022-10-04 |
EP4021496A1 (en) | 2022-07-06 |
US11850284B2 (en) | 2023-12-26 |
US20230093460A1 (en) | 2023-03-23 |
WO2021042060A1 (en) | 2021-03-04 |
CA3149421A1 (en) | 2021-03-04 |
US20230085308A1 (en) | 2023-03-16 |
AU2020336992A1 (en) | 2022-04-14 |
US20230032060A1 (en) | 2023-02-02 |
IL290862A (en) | 2022-04-01 |
US20230093888A1 (en) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002342A (es) | Composiciones y metodos para suministro de acidos nucleicos a celulas. | |
MX2023006403A (es) | Composiciones y métodos para el suministro de ácidos nucleicos a las células. | |
JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
EP4257611A3 (en) | Anti-muc1 antibody | |
MX2023002480A (es) | "composiciones y métodos para el suministro de ácidos nucleicos a las células. | |
AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
NZ603226A (en) | Anti-c5a antibodies and methods for using the antibodies | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
MY196874A (en) | Humanized anti-basigin antibodies and the use thereof | |
UA120048C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
MX2022001942A (es) | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. | |
MX2022011951A (es) | Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos. | |
AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso | |
JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
JP2017511152A5 (es) | ||
MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. | |
WO2024081736A3 (en) | Compositions and methods of using cell-penetrating antibodies | |
PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t |